In­cyte scores much need­ed PhI­II suc­cess — and of course it’s de­liv­ered by rux­oli­tinib

6 years ago
R&D

Sanofi/Re­gen­eron Dupix­ent; Alk­er­mes' an­tipsy­chot­ic get dates with the FDA; Con­cert wins re­prieve in In­cyte patent ...

6 years ago
News Briefing

Can we make the an­tibi­ot­ic mar­ket great again?

6 years ago
R&D
In Focus

The FDA un­veils a new reg­u­la­to­ry frame­work to speed along gene ther­a­pies, re­ward­ing the lead­ing play­ers

6 years ago
Bioregnum
Opinion

Mike Bloomberg joins a grow­ing cho­rus of De­mo­c­ra­t­ic pres­i­den­tial can­di­dates threat­en­ing to go af­ter drug patents

6 years ago
People
Pharma

Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a ...

6 years ago
People
Startups

J&J's Spra­va­to gets no love from NICE, jeop­ar­diz­ing its prospects in the UK

6 years ago
Pharma

The FTC and New York state ac­cuse Mar­tin Shkre­li of run­ning a drug mo­nop­oly. They plan to squash it — and ...

6 years ago
People
FDA+

Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

6 years ago
R&D

Civi­ca and Blue Cross Blue Shield launch new ven­ture to low­er gener­ic prices

6 years ago
R&D

PPD, Schrödinger, Beam set terms for IPO; FDA ex­pands use of Mer­ck­'s Di­fi­cid

6 years ago
News Briefing

Mer­ck KGaA match­es lofty R&D goals with €250M in­vest­ment in­to a new clin­i­cal man­u­fac­tur­ing site in Switzer­land

6 years ago
R&D

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

6 years ago
R&D
Pharma

Af­ter a brief break, As­traZeneca is back at di­vest­ing — hand­ing off hy­per­ten­sion meds for $350M

6 years ago
Deals

Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

6 years ago
R&D

Sor­ren­to shrugs off an anony­mous pri­vate eq­ui­ty group’s $1B of­fer to buy the com­pa­ny

6 years ago
R&D

Ab­b­Vie do­nates $1M+ of the HIV drug that Chi­na is now rec­om­mend­ing for coro­n­avirus treat­ment

6 years ago
China
Coronavirus

Ab­b­Vie and Al­ler­gan di­vesti­tures are in, and an old As­traZeneca drug comes home

6 years ago
Deals

As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

6 years ago
R&D
Pharma

Bruce Booth and Saman­tha Truex's lat­est ven­ture aims just above Hu­mi­ra

6 years ago
Financing
Startups

Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

6 years ago
Deals

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

6 years ago
Pharma

Gilead dusts off a failed Ebo­la drug as coro­n­avirus spreads; Ex­elix­is boasts pos­i­tive Ph I/II da­ta

6 years ago
News Briefing
Coronavirus

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma ...

6 years ago
Outsourcing
Cell/Gene Tx
First page Previous page 873874875876877878879 Next page Last page
A service from the Financial Times